Following disappointing results from Arqule Inc.’s Phase III study in non-small-cell lung cancer (NSCLC) a year ago, analysts had all but written off tivantinib in that indication. But detailed data reported at this week’s European Cancer Congress in Amsterdam suggested the oral MET inhibitor might have an opportunity in NSCLC after all.